TABLE 1.

In vitro data for NRI compounds and control antibacterials

Antibacterial compound	IC50 (μM)				MIC (μg/ml)		Jijoye B-cell cytotoxicity LD50 (μg/ml)c
	S. pneumoniae transcription/translation	S. pneumoniae translation	E. coli translation	Eukaryotic translation	S. pneumoniae ATCC 6303a	S. pneumoniae ATCC 7257b
A-72310	10	5	5	>100	>64	32	>100
A-692345		14	19	>100	32	8	>100
Chloramphenicol	10	3.4	0.5	>100	2	1	>100
Linezolid	1.6	2.9	1.2	>100	2	0.5	>100
Minocycline		1.2	3.5		>0.06	>0.06	20
Oxytetracycline		5.4	30		0.5	0.125	>100
Tetracycline	0.35	0.55	2.6	>100	0.5	0.125	50
Erythromycin	0.3	0.4	0.25	>100	≤0.06	≤0.06	>100
Lincomycin		0.2	10.9		0.125	≤0.06	>100
Neamine		0.65	4		32	16	>100
Puromycin		0.1	0.2		1	1	<0.8
Streptomycin	<0.02	0.03	0.04	>100	>64	16	>100
Thiostrepton		0.2	0.5		≤0.06	≤0.06	>50
Rifampicin	0.1	>100	>100		≤0.06	≤0.06	>100
Cycloheximide	>100	>100	>100	0.3	>64	>64	1.5
Ciprofloxacin	>100	>100	>100	>100	0.5	8	70
Levofloxacin		>100	>100		1	16	>100
Norfloxacin		>100	>100		1	32	110

^aQuinolone susceptible.

^bQuinolone resistant.

^cLD₅₀, 50% lethal dose.